polo样激酶作为免疫调节剂：癌症免疫治疗的新前沿。

IF 17.5 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2025-08-29 DOI:10.1016/j.trecan.2025.08.003

Tanya Jaiswal, Gagan Chhabra, Nihal Ahmad

引用次数: 0

摘要

癌症免疫疗法已经改变了治疗方式，但面临着免疫逃避和毒性等挑战。polo样激酶（PLKs）在肿瘤中经常失调，正在成为关键的免疫调节剂。PLK抑制联合免疫治疗可以克服耐药性，增强抗肿瘤反应，改善临床结果，为癌症治疗提供了一种最有效的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Polo-like kinases as immune modulators: a new frontier in cancer immunotherapy.

Cancer immunotherapy has transformed treatment but faces challenges such as immune evasion and toxicity. Polo-like kinases (PLKs), frequently dysregulated in tumors, are emerging as key immune modulators. Combining PLK inhibition with immunotherapy may overcome resistance, enhance antitumor responses, and improve clinical outcomes, offering an optimally efficient strategy for cancer treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.